0 01/01/2025 31/12/2025 2025-12-31 false false false false false false false true false false true false false false false true true false No description of principal activities is disclosed 2025-01-01 Sage Accounts Production 24.0 - FRS102_2024 xbrli:pure xbrli:shares iso4217:GBP 12471794 2025-01-01 2025-12-31 12471794 2025-12-31 12471794 2024-12-31 12471794 2024-01-01 2024-12-31 12471794 2024-12-31 12471794 2023-12-31 12471794 core:PlantMachinery 2025-01-01 2025-12-31 12471794 core:FurnitureFittingsToolsEquipment 2025-01-01 2025-12-31 12471794 bus:RegisteredOffice 2025-01-01 2025-12-31 12471794 bus:Director1 2025-01-01 2025-12-31 12471794 core:PlantMachinery 2024-12-31 12471794 core:FurnitureFittingsToolsEquipment 2024-12-31 12471794 core:PlantMachinery 2025-12-31 12471794 core:FurnitureFittingsToolsEquipment 2025-12-31 12471794 core:WithinOneYear 2025-12-31 12471794 core:WithinOneYear 2024-12-31 12471794 core:AfterOneYear 2025-12-31 12471794 core:AfterOneYear 2024-12-31 12471794 core:ShareCapital 2025-12-31 12471794 core:ShareCapital 2024-12-31 12471794 core:RetainedEarningsAccumulatedLosses 2025-12-31 12471794 core:RetainedEarningsAccumulatedLosses 2024-12-31 12471794 core:PlantMachinery 2024-12-31 12471794 core:FurnitureFittingsToolsEquipment 2024-12-31 12471794 bus:Director1 2024-12-31 12471794 bus:Director1 2025-12-31 12471794 bus:Director1 2023-12-31 12471794 bus:Director1 2024-12-31 12471794 bus:SmallEntities 2025-01-01 2025-12-31 12471794 bus:AuditExempt-NoAccountantsReport 2025-01-01 2025-12-31 12471794 bus:SmallCompaniesRegimeForAccounts 2025-01-01 2025-12-31 12471794 bus:PrivateLimitedCompanyLtd 2025-01-01 2025-12-31 12471794 bus:FullAccounts 2025-01-01 2025-12-31
Company registration number: 12471794
Cohen Global Limited
Unaudited filleted financial statements
31 December 2025
Cohen Global Limited
Contents
Directors and other information
Statement of financial position
Notes to the financial statements
Cohen Global Limited
Directors and other information

| Director | Mr Daniel Cohen
| Company number | 12471794
| Registered office | 2nd Floor, 32-33 Gosfield Street,
|  | London
|  | W1W 6HL

Cohen Global Limited
Statement of financial position
31 December 2025

|  |  | 2025 |  |  |  | 2024 |  |
|  | Note | £ |  | £ |  | £ |  | £
Fixed assets |  |  |  |  |  |  |  |  |
Tangible assets |  | 5 | 51,131 |  |  |  | 80,360 |  |
|  |  | _______ |  |  |  | _______ |  |
|  |  |  |  | 51,131 |  |  |  | 80,360
Current assets |  |  |  |  |  |  |  |  |
Debtors |  | 6 | 368,260 |  |  |  | 598,849 |  |
Cash at bank and in hand |  |  | 3,723 |  |  |  | 2,655 |  |
|  |  | _______ |  |  |  | _______ |  |
|  |  | 371,983 |  |  |  | 601,504 |  |
Creditors: amounts falling due |  |  |  |  |  |  |  |  |
within one year |  | 7 | ( 7,228,365) |  |  |  | ( 5,994,400) |  |
|  |  | _______ |  |  |  | _______ |  |
Net current liabilities |  |  |  |  | ( 6,856,382) |  |  |  | ( 5,392,896)
|  |  |  |  | _______ |  |  |  | _______
Total assets less current liabilities |  |  |  |  | ( 6,805,251) |  |  |  | ( 5,312,536)
Creditors: amounts falling due |  |  |  |  |  |  |  |  |
after more than one year |  | 8 |  |  | ( 529,618) |  |  |  | ( 529,618)
|  |  |  |  | _______ |  |  |  | _______
Net liabilities |  |  |  |  | ( 7,334,869) |  |  |  | ( 5,842,154)
|  |  |  |  | _______ |  |  |  | _______
Capital and reserves |  |  |  |  |  |  |  |  |
Called up share capital |  |  |  |  | 100 |  |  |  | 100
Profit and loss account |  |  |  |  | ( 7,334,969) |  |  |  | ( 5,842,254)
|  |  |  |  | _______ |  |  |  | _______
Shareholder deficit |  |  |  |  | ( 7,334,869) |  |  |  | ( 5,842,154)
|  |  |  |  | _______ |  |  |  | _______

For the year ending 31 December 2025 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
Director's responsibilities:
- The member has not required the company to obtain an audit of its financial statements for the year in question in accordance with section 476;
- The director acknowledges their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.
These financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with Section 1A of FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
In accordance with section 444 of the Companies Act 2006, the statement of comprehensive income has not been delivered.
These financial statements were approved by the board of directors and authorised for issue on 01 April 2026 , and are signed on behalf of the board by:
Mr Daniel Cohen
Director
Company registration number: 12471794
Cohen Global Limited
Notes to the financial statements
Year ended 31 December 2025
1. General information
The company is a private company limited by shares, registered in United Kingdom. The address of the registered office is 2nd Floor, 32-33 Gosfield Street,, London, W1W 6HL.
2. Statement of compliance
These financial statements have been prepared in compliance with the provisions of FRS 102, Section 1A, 'The Financial Reporting Standard applicable in the UK and Republic of Ireland'.
3. Accounting policies
Basis of preparation
The financial statements have been prepared on the historical cost basis, as modified by the revaluation of certain financial assets and liabilities and investment properties measured at fair value through profit or loss.
The financial statements are prepared in sterling, which is the functional currency of the entity.
Taxation
The taxation expense represents the aggregate amount of current and deferred tax recognised in the reporting period. Tax is recognised in the statement of comprehensive income, except to the extent that it relates to items recognised in other comprehensive income or directly in capital and reserves. In this case, tax is recognised in other comprehensive income or directly in capital and reserves, respectively. Current tax is recognised on taxable profit for the current and past periods. Current tax is measured at the amounts of tax expected to pay or recover using the tax rates and laws that have been enacted or substantively enacted at the reporting date.
Deferred tax is recognised in respect of all timing differences at the reporting date. Unrelieved tax losses and other deferred tax assets are recognised to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits. Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date that are expected to apply to the reversal of the timing difference.
Research and development
Research expenditure is written off in the year in which it is incurred. Development expenditure incurred is capitalised as an intangible asset only when all of the following criteria are met: - It is technically feasible to complete the intangible asset so that it will be available for use or sale; - There is the intention to complete the intangible asset and use or sell it; - There is the ability to use or sell the intangible asset; - The use or sale of the intangible asset will generate probable future economic benefits; - There are adequate technical, financial and other resources available to complete the development and to use or sell the intangible asset; and - The expenditure attributable to the intangible asset during its development can be measured reliably. Expenditure that does not meet the above criteria is expensed as incurred.
Tangible assets
tangible assets are initially recorded at cost, and are subsequently stated at cost less any accumulated depreciation and impairment losses. Any tangible assets carried at revalued amounts are recorded at the fair value at the date of revaluation less any subsequent accumulated depreciation and subsequent accumulated impairment losses. An increase in the carrying amount of an asset as a result of a revaluation, is recognised in other comprehensive income and accumulated in capital and reserves, except to the extent it reverses a revaluation decrease of the same asset previously recognised in profit or loss. A decrease in the carrying amount of an asset as a result of revaluation is recognised in other comprehensive income to the extent of any previously recognised revaluation increase accumulated in capital and reserves in respect of that asset. Where a revaluation decrease exceeds the accumulated revaluation gains accumulated in capital and reserves in respect of that asset, the excess shall be recognised in profit or loss.
Depreciation
Depreciation is calculated so as to write off the cost or valuation of an asset, less its residual value, over the useful economic life of that asset as follows:

| Plant and Machinery | - | 25 % | straight line
| Lab equipment | - | 25 % | straight line

If there is an indication that there has been a significant change in depreciation rate, useful life or residual value of tangible assets, the depreciation is revised prospectively to reflect the new estimates.
Impairment
A review for indicators of impairment is carried out at each reporting date, with the recoverable amount being estimated where such indicators exist. Where the carrying value exceeds the recoverable amount, the asset is impaired accordingly. Prior impairments are also reviewed for possible reversal at each reporting date. When it is not possible to estimate the recoverable amount of an individual asset, an estimate is made of the recoverable amount of the cash-generating unit to which the asset belongs. The cash-generating unit is the smallest identifiable group of assets that includes the asset and generates cash inflows that are largely independent of the cash inflows from other assets or groups of assets.
Financial instruments
A financial asset or a financial liability is recognised only when the company becomes a party to the contractual provisions of the instrument. Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Debt instruments are subsequently measured at amortised cost. Where investments in non-convertible preference shares and non-puttable ordinary shares or preference shares are publicly traded or their fair value can otherwise be measured reliably, the investment is subsequently measured at fair value with changes in fair value recognised in profit or loss. All other such investments are subsequently measured at cost less impairment. Other financial instruments, including derivatives, are initially recognised at fair value, unless payment for an asset is deferred beyond normal business terms or financed at a rate of interest that is not a market rate, in which case the asset is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Other financial instruments are subsequently measured at fair value, with any changes recognised in profit or loss, with the exception of hedging instruments in a designated hedging relationship.
Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately. For all equity instruments regardless of significance, and other financial assets that are individually significant, these are assessed individually for impairment. Other financial assets or either assessed individually or grouped on the basis of similar credit risk characteristics. Any reversals of impairment are recognised in profit or loss immediately, to the extent that the reversal does not result in a carrying amount of the financial asset that exceeds what the carrying amount would have been had the impairment not previously been recognised.
Defined contribution plans
Contributions to defined contribution plans are recognised as an expense in the period in which the related service is provided. Prepaid contributions are recognised as an asset to the extent that the prepayment will lead to a reduction in future payments or a cash refund. When contributions are not expected to be settled wholly within 12 months of the end of the reporting date in which the employees render the related service, the liability is measured on a discounted present value basis. The unwinding of the discount is recognised in finance costs in profit or loss in the period in which it arises.
4. Employee numbers
The average number of persons employed by the company during the year amounted to Nil (2024: 5 ).
5. Tangible assets

|  | Plant and machinery | Fixtures, fittings and equipment | Total |  |  |  |
|  | £ | £ | £ |  |  |  |
| Cost |  |  |  |  |  |  |
| At 1 January 2025 and 31 December 2025 | 107,219 | 60,000 | 167,219 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| Depreciation |  |  |  |  |  |  |
| At 1 January 2025 | 29,284 | 57,575 | 86,859 |  |  |  |
| Charge for the year | 26,804 | 2,425 | 29,229 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| At 31 December 2025 | 56,088 | 60,000 | 116,088 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| Carrying amount |  |  |  |  |  |  |
| At 31 December 2025 | 51,131 | - | 51,131 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |
| At 31 December 2024 | 77,935 | 2,425 | 80,360 |  |  |  |
|  | _______ | _______ | _______ |  |  |  |

6. Debtors

|  |  | 2025 | 2024
|  |  | £ | £
| Other debtors |  | 368,260 | 598,849
|  |  | _______ | _______

7. Creditors: amounts falling due within one year

|  |  | 2025 | 2024
|  |  | £ | £
| Trade creditors |  | 355,810 | 492,313
| Amounts owed to group undertakings and undertakings in which the company has a participating interest |  | 3,649,933 | 2,761,001
| Corporation tax |  | 20 | -
| Social security and other taxes |  | 5,613 | 9,151
| Other creditors |  | 3,216,989 | 2,731,935
|  |  | _______ | _______
|  |  | 7,228,365 | 5,994,400
|  |  | _______ | _______

8. Creditors: amounts falling due after more than one year

|  |  | 2025 | 2024
|  |  | £ | £
| Other creditors |  | 529,618 | 529,618
|  |  | _______ | _______

9. Directors advances, credits and guarantees

| During the year the director entered into the following advances and credits with the company: |  |  |  |  |  |
2025 |  |  |  |  |  |  |
|  | Balance brought forward | Advances /(credits) to the director | Balance o/standing |  |  |
|  | £ | £ | £ |  |  |
| Mr Daniel Cohen | ( 2,606,226) | ( 98,000) | ( 2,704,226) |  |  |
|  | _______ | _______ | _______ |  |  |
2024 |  |  |  |  |  |  |
|  | Balance brought forward | Advances /(credits) to the director | Balance o/standing |  |  |
|  | £ | £ | £ |  |  |
| Mr Daniel Cohen | ( 2,606,226) | - | ( 2,606,226) |  |  |
|  | _______ | _______ | _______ |  |  |

10. Related party transactions
During the year the company entered into the following transactions with related parties:

|  | Transaction value |  | Balance owed by/(owed to) |
|  | 2025 | 2024 | 2025 | 2024
|  | £ | £ | £ | £
| Radella Pharmaceuticals LLC | - | - | 3,556,932 | ( 2,668,001)
|  | _______ | _______ | _______ | _______

At the year end the company owed Radella Pharmaceuticals Inc £3,556,932 (2024 - £2,668,001). The company is controlled by the director Mr Daniel Cohen .
11. Controlling party
The company was conntrolled by the director throughout the year.